HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Rapid autopsy holds ‘great power’ for deciphering tumor heterogeneity in various cancers
• Should rapid autopsy be requested for every participant in a clinical trial?
• Adjuvant therapy for pancreas cancer: Real progress at last? Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• ‘Exaggerated’ early clinical trial results may create false hope
• Chronic diseases account for more than 20% of cancer risk
• Dacomitinib new first-line treatment option for EGFR-positive non-small cell lung cancer
• AMA inaugurates Barbara L. McAneny, MD, as president
• Once-weekly carfilzomib effective for relapsed, refractory myeloma
• Responses to CAR T-cell therapy deepen over time for lymphoma
• Antacid, aspirin combination slows disease progression in Barrett’s esophagus
• Neoadjuvant androgen deprivation therapy with enzalutamide active in high-risk localized prostate cancer
• Erdafitinib shows promise for metastatic urothelial carcinoma
• Nivolumab shows durable benefit for advanced melanoma
• Preoperative chemoradiotherapy improves pancreatic cancer survival
• Combination therapy with SD-101, pembrolizumab shows promise for metastatic melanoma
• Use of heated chemotherapy during surgery does not improve colorectal cancer survival
• JTX-2011 shows activity for gastric, triple-negative breast cancers
• First-line pembrolizumab improves survival for PD-L1-positive non-small cell lung cancer
• Ribociclib plus fulvestrant improves PFS for advanced breast cancer
• Nivolumab plus chemotherapy prolongs PFS in lung cancer with PD-L1 less than 1%
• Women less likely than men to receive intensive treatment for head, neck cancers
• Treatment of myelofibrosis with JAK inhibitors may increase risk for aggressive lymphoma
• ASCO updates guideline on use of bisphosphonates for multiple myeloma
• Colorectal cancer screening rates vary significantly among states, counties
• Breast cancer has worse financial impact on black women
• Fewer men undergoing prostate cancer screening, treatment
• Subgroup of children with medulloblastoma can receive less aggressive treatment
• Having an abortion may increase risk for blood clots
• Automated approach may improve cervical cancer screening
• Hepatitis B screening remains important prior to anticancer therapy
• ASCO updates fertility preservation guidelines
• Researchers identify distinct genetic subtypes of diffuse large B-cell lymphoma
• Venetoclax receives regular approval for CLL, small lymphocytic lymphoma
• FDA grants priority review to talazoparib for breast cancer subtype
• FDA clears Paxman scalp-cooling system for all patients with solid tumors
• FDA grants orphan drug designation to PU-H71 for myelofibrosis
• FDA grants priority review to Gardasil 9 for adults aged 27 to 45
• FDA approves Keytruda for cervical cancer
• Cincinnati Children’s Hospital Medical Center named nation’s best for pediatric cancer
• UCLA physician-scientist named ‘great immigrant’
• Roswell Park Comprehensive Cancer Center researcher receives award to study kidney cancer vaccine
• Frontline Tecentriq plus chemotherapy improves lung cancer survival
• NBTXR3 with radiotherapy doubles responses for soft tissue sarcoma